Jesse L. Goodman
Scientific & Medical ExpertDr. Jesse L. Goodman, M.D. M.P.H. was an Independent Director at BiomX Inc. since March 15, 2024 until February 11, 2026. He has been Director at Adaptive Phage Therapeutics, Inc. since September 2021. He had been Independent Non-Executive Director at GSK plc (formerly known as GlaxoSmithKline plc) since January 1, 2016 until May 7, 2025 and serves as its Scientific & Medical Expert. Dr. Goodman is a Professor of Medicine at Georgetown University. Dr. Goodman serves as an Independent Director at Intellia Therapeutics, Inc since October 31, 2018. Dr. Goodman directs the Georgetown University Center on Medical Product Access, Safety and Stewardship (COMPASS). Dr. Goodman served in senior leadership positions at the US Food and Drug Administration ("FDA"), including as FDA's Chief Scientist, Deputy Commissioner for Science and Public Health and Director of the Center for Biologics Evaluation and Research (CBER). He played a leadership role in developing the FDA Regulatory Science and Medical Countermeasures Initiatives and has worked collaboratively with industry, academia, government and global public health and regulatory partners to prepare for and respond to major public health threats, including emerging infectious diseases, disasters and terrorism. He led the FDA response to West Nile Virus and to the 2009 H1N1 influenza pandemic and served on the Senior Leadership Team for the 2010 White House Medical Countermeasure Review. Dr. Goodman is a leader in public health who has a wealth of expertise spanning science, medicine, vaccines, regulation and public health and has a proven record in addressing pressing public health needs from both the academic and federal sectors. As Senior Advisor to the FDA Commissioner from September 1998 to 2000. Dr. Goodman co-Chaired the US Task Force on Antimicrobial Resistance, Prior to joining the FDA, he serves as Director of the Division of Infectious Diseases and was Professor of Medicine at the University of Minnesota. He was Board Member and President at United States Pharmacopeia (USP); Board Member, Scientific Counselors for Infectious Diseases, Centers for Disease Control and Prevention (CDC) also Member, US National Academy of Medicine. He was a Member of the Decade of Vaccines Research and Development Working Group, which contributed to the 2012 Global Vaccine Action Plan. He is an active clinician who serves as Attending Physician in Infectious Diseases. Dr. Goodman is Board Certified in Internal Medicine, Infectious Diseases and Oncology and was elected to the American Society for Clinical Investigation and to the Institute (National Academy) of Medicine. He underwent residency and fellowship training in Medicine, Infectious Diseases and Oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles (UCLA), where he was also Chief Medical Resident. He received a B.S. in Biology from Harvard College, his masters in public health from the University of Minnesota and M.D. from the Albert Einstein College of Medicine.
Positions
- Company NameGSK plcStock CodeGSKPositionScientific & Medical ExpertColleagues
- JBJulie Belita BrownCFO & Executive Director
- JRJonathan Richard SymondsChair
- LVLuke Victor MielsCEO & Director
- SRShobie RamakrishnanChief Digital & Technology Officer
- TWTony WoodChief Scientific Officer and Head of R&D
- CACharles A. BancroftSenior Independent Non-Executive Director
- WMWendy Mira BeckerIndependent Non-Executive Director
